Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pulmonx Corporation is a medical technology company focused on developing and commercializing minimally invasive treatments for severe pulmonary diseases, primarily emphysema, a form of chronic obstructive pulmonary disease (COPD). The company operates within the medical devices and interventional pulmonology industries, targeting patients who remain symptomatic despite optimal medical therapy. Pulmonx’s core value proposition is offering less invasive alternatives to lung volume reduction surgery, aiming to improve lung function, exercise capacity, and quality of life.
The company’s primary revenue driver is its proprietary Zephyr Endobronchial Valve system, which is designed to occlude diseased portions of the lung to reduce hyperinflation. Pulmonx primarily serves hospitals and specialized pulmonary centers, with a customer base consisting of interventional pulmonologists and thoracic specialists. Founded in 1998, Pulmonx spent many years in clinical development and regulatory validation, culminating in U.S. FDA approval for the Zephyr Valve in 2018 and its initial public offering in 2020, which expanded its commercial and clinical footprint.
Business Operations
Pulmonx operates as a single-reportable-segment company centered on the development, manufacturing, and commercialization of its lung volume reduction technologies. Its main commercial products include the Zephyr Endobronchial Valve and the Chartis Pulmonary Assessment System, which is used to assess collateral ventilation and determine patient eligibility for valve therapy. Revenue is generated primarily through direct sales of these devices and associated procedural usage in hospital settings.
The company conducts operations in both domestic and international markets, with direct sales forces in key regions and distributor relationships in select countries. Pulmonx controls proprietary device designs, clinical data, and procedural know-how, supported by a portfolio of patents. Manufacturing is outsourced to qualified third-party suppliers, while Pulmonx maintains internal oversight of quality, regulatory compliance, and clinical education. The company also operates wholly owned subsidiaries, including Pulmonx International Sàrl, which supports non-U.S. commercial activities.
Strategic Position & Investments
Pulmonx’s strategic direction is focused on expanding adoption of bronchoscopic lung volume reduction as a standard of care for severe emphysema. Growth initiatives include increasing physician training, expanding reimbursement coverage, and driving patient awareness through clinical evidence generation. The company continues to invest in post-market clinical studies and registries to support broader guideline inclusion and payer acceptance.
Strategically, Pulmonx has prioritized organic growth over large-scale acquisitions, with investments concentrated on product enhancements, next-generation valve technologies, and data-driven patient selection tools. The company has not disclosed significant transformative acquisitions but continues to evaluate complementary technologies within interventional pulmonology and advanced COPD treatment. Its portfolio remains centered on internally developed platforms rather than a diversified set of subsidiaries.
Geographic Footprint
Pulmonx is headquartered in Redwood City, California, and maintains a strong operational presence in North America and Europe, which together represent the majority of its revenue. The company has established direct commercial operations in major European markets, including Germany, France, and the United Kingdom, where bronchoscopic lung volume reduction has seen earlier adoption.
Beyond Europe and the United States, Pulmonx distributes its products in parts of Asia-Pacific and Latin America through third-party distributors. While international markets represent a smaller share of total revenue compared to the U.S., they are a key component of the company’s long-term growth strategy, particularly as regulatory approvals and reimbursement pathways expand globally.
Leadership & Governance
Pulmonx is led by an experienced management team with backgrounds in medical devices, commercialization, and regulated healthcare markets. The leadership emphasizes clinical evidence, disciplined growth, and close collaboration with physician partners as core elements of its strategic vision. Corporate governance is overseen by a board of directors with expertise in life sciences, finance, and public company oversight.
Key executives include:
- Glen French – President and Chief Executive Officer
- Dave Dove – Chief Financial Officer
- Caroline Fenske – Chief Commercial Officer
- Karen H. King – Chief Legal Officer and Corporate Secretary
- Mark G. Ralston – Chief Technology Officer
The leadership team’s stated philosophy centers on advancing patient outcomes through evidence-based innovation while scaling operations responsibly in a highly regulated medical device environment.